Company Encyclopedia
View More
name
iShares Neuroscience And Healthcare ETF
IBRN.US
News
View More

U.S. Stock Market Midday Update: FDA Breakthrough Therapy Designation Boosts Praxis Stock Price by 15.83%, Analysts Optimistic About Outlook

Praxis Precision Medicines rose 15.83%; Amgen fell 0.49%, with a transaction volume of USD 197 million; Ultragenyx Pharmaceuticals fell 43.96%, with a transaction volume of USD 183 million; AbbVie rose 0.54%, with a transaction volume of USD 134 million; Gilead Sciences fell 0.14%, with a market value of USD 154.5 billion

Tracking Unusual Activity·
US
PRAX
+13.66%
Tracking Unusual Activity·
US
PRAX
+13.66%

Praxis Precision Medicines: Breakthrough Neurology Pipeline and Regulatory Momentum Support Upside and Buy Rating

Francois Brisebois from LifeSci Capital has maintained a Buy rating on Praxis Precision Medicines, raising the price target to $534.00. This decision is based on the company's advancing neurology pipeline and recent regulatory momentum, particularly the FDA's Breakthrough Therapy Designation for ulixacaltamide. Brisebois anticipates significant market uptake and a favorable long-term revenue outlook, supported by positive clinical data and upcoming NDA filings. Jefferies also maintains a Buy rating with a $450.00 price target, reflecting confidence in the company's growth potential.

Tip Ranks·
US
PRAX
+13.66%
Tip Ranks·
US
PRAX
+13.66%

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High - Time to Buy?

Praxis Precision Medicines (NASDAQ:PRAX) reached a new 52-week high of $315.03, up from a previous close of $268.95. Analysts have set varied price targets, with Oppenheimer raising its target to $750.00. The stock has a consensus rating of "Moderate Buy" and an average target price of $426.20. The company reported an EPS of ($3.36), beating estimates. Insider trading activity includes significant sales by executives. Institutional investors hold 67.84% of the stock, indicating strong institutional interest.

Market Beat·
US
PRAX
+13.66%
Market Beat·
US
PRAX
+13.66%

Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday

Top Wall Street analysts have revised their price targets for several stocks. Praxis Precision Medicines (NASDAQ:PRAX) saw its target raised from $507 to $843 by BTIG, maintaining a Buy rating. Other notable changes include Needham raising Autolus Therapeutics (NASDAQ:AUTL) from $10 to $11, while JP Morgan cut KB Home (NYSE:KBH) from $71 to $50. Amicus Therapeutics (NASDAQ:FOLD) was downgraded by Leerink Partners from $17 to $14.5. Clear Street raised targets for Planet Labs (NYSE:PL) and Intuitive Machines (NASDAQ:LUNR), while Vail Resorts (NYSE:MTN) saw a slight decrease in its target from $237 to $234.

benzinga_article·
US
LUNR
+1.61%
US
PRAX
+13.66%
benzinga_article·
US
LUNR
+1.61%
US
PRAX
+13.66%

Sector Update: Health Care Stocks Mixed Premarket Monday

Health care stocks showed mixed performance in premarket trading on Monday. The State Street Health Care Select Sector SPDR ETF (XLV) was slightly down, while the iShares Biotechnology ETF (IBB) rose by 0.2%. Praxis Precision Medicines (PRAX) surged over 14% after receiving Breakthrough Therapy Designation from the FDA for ulixacaltamide. Conversely, Genmab (GMAB) fell more than 2% as it halted development of acasunlimab. Novo Nordisk (NVO) saw a decline of over 1% after cutting the prices of its obesity drug Wegovy in some Chinese provinces.

fidelity·
US
NVO
-1.40%
US
PRAX
+13.66%
fidelity·
US
NVO
-1.40%
US
PRAX
+13.66%
© 2025 Longbridge｜Disclaimer